Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity

Tissue Antigens

Volumn 52, Issue 1, 1998, Pages 44-50

  Bresciani, A ^a,b   Pirozzi, G ^a   Spera, M ^a,b   Lombardi, M L ^a   Ambrosone, L ^b   Migliaresi, S ^b   Ferrone, S ^c   Manzo, C ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Double determinant immunoassay; Serum HLA I; Serum 2 free HLA I heavy chain; Systemic lupus erythematosus; Western blot

Indexed keywords

HLA ANTIGEN CLASS 1;

APOPTOSIS; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOBLOTTING; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031843674     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb03022.x     Document Type: Article

References (35)

1. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 1984: 44: 4679-87.
2. Ferrone S, Yamamura M, Grosse-Wilde H, Pouletty P. Summary of the serum-soluble HLA class I antigen component. In: Tsuji K, Aizawa M, Sasazuki T, ed. HLA 1991. Proc 11th Intl Histocompatibility Workshop Conference. Vol 2. Oxford: Oxford University Press, 1992: 1057-61.
3. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today 1995: 16: 124-7.
4. 2-μ-free HLA class I-chains. Qualitative and quantitative characterization. J Immunol 1993: 151: 2613-22.
5. Buelow R, Burlingham WJ, Clayberger C. Immunomodulation by soluble HLA class I. Transplantation 1995: 59: 649-54.
6. Puppo F, Indiveri F, Scudeletti M, Ferrone S. Soluble HLA antigens: new roles and uses. Immunol Today 1997: 18: 154-5.
7. Zavazava N, Hausmann R, Muller-Ruchholtz W. Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA. Transplantation 1991: 51: 838-42.
8. Hausmann R, Zavazava N, Steinmann J, Muller-Ruchholtz W. Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin Exp Immunol 1993: 91: 183-8.
9. Carbone E, Terrazzano G, Colonna M et al. Natural killer clones recognize specific soluble HLA class I molecules. Eur J Immunol 1996: 26: 683-9.
10. Zavazava N, Krönke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996: 2: 1005-10.
11. Kotzin BL. Systemic lupus erythematosus. Cell 1996: 85: 303-6.
12. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol 1987: 139: 1840-9.
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982: 25: 1271-7.
14. Urowitz MR, Gladman DD, Tozman EC, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984: 11: 783-7.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992: 35: 630-40.
16. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992: 10: 541-7.
17. 2-μ-free HLA-B heavy chains. In: Tsuji K, Aizawa M, Sasazuki T, ed. Proc of the 11th International Histocompatibility Workshop and Conference. II. Oxford: Oxford University Press, 1992: 393-5.
18. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986: 137: 2299-306.
19. Pellegrino MA, Ng A-K, Russo C, Ferrone S. Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 1982: 34: 18-23.
20. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone, S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 1993: 161: 239-56.
21. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 1989: 8: 85-95.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970: 227: 680-5.
23. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 1978: 80: 849-57.
24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979: 76: 4350-4.
25. Tsuchiya N, Shiota M, Yamaguchi A, Ito K. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 1996: 39: 792-6.
26. Lulli P, Sebastiani GD, Trabace S et al. HLA antigens in Italian patients with systemic lupus erythematosus: evidence for the association of DQw2 with the autoantibody response to extractable nuclear antigens. Clin Exp Rheumatol 1991: 9: 475-9.
27. Baur MP, Neugebauer M, Deppe H et al. Population analysis on the basis of deduced haplotypes from random families. Proceedings of the 9th International Histocompatibility Workshop and Conference. Berlin: Springer-Verlag, 1984: 133-47.
28. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. J Immunol 1977: 118: 1004-9.
29. Dobbe LM, Stam NJ, Neefjes JJ, Giphart MJ. Biochemical complexity of serum HLA class I molecules. Immunogenetics 1988: 27: 203-10.
30. Krangel MS. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med 1986: 163: 1173-90.
31. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987: 70: 562-9.
32. Hillebrand K, Moritz T, Westhoff U, Niederle N, Grosse-Wilde H. Soluble HLA class I and beta-2-microglobulin plasma concentrations during interferon treatment of chronic myelogenous leukemia. Vox Sang 1994: 67: 310-4.
33. Aulitzky WE, Grosse-Wilde H, Westhoff U et al. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-γ). Clin Exp Immunol 1991: 86: 236-9.
34. Adamashvili IM, McDonald JC, Fraser PA, Milford EL, Pressly TA, Gelder FB. Soluble class I HLA antigens in patients with rheumatoid arthritis and their families. J Rheumatol 1995: 22: 1025-31.
35. Filaci G, Contini P, Brenci S et al. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. Hum Immunol 1997: 54: 54-62.